TolerogenixX is a biopharmaceutical company that specializes in developing personalized cellular therapies aimed at achieving sustained immune tolerance, particularly in the context of organ transplantation and autoimmune diseases. The company's proprietary technology, known as Modified Immune Cells (MIC), involves the modification of peripheral blood mononuclear cells (PBMCs) harvested from organ donors. These modified cells are then infused into transplant recipients prior to surgery, allowing for a tailored immunosuppressive approach that specifically targets unwanted immune responses while preserving the body's ability to defend against infections and tumors. This innovative method aims to reduce the reliance on conventional immunosuppressive drugs, which often come with significant side effects and risks.

The TolerogenixX approach has shown promising results in clinical trials, including a Phase I study that demonstrated the safety and efficacy of MIC therapy in kidney transplant recipients. Patients treated with MICs exhibited stable renal graft function and a lack of acute rejection episodes, while also experiencing fewer complications compared to those receiving standard immunosuppressive therapy. The technology is not only applicable to transplantation but also holds potential for treating various autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis. By focusing on individualized treatment and minimizing adverse effects, TolerogenixX aims to transform the landscape of immunosuppression and improve the quality of life for patients undergoing transplantation and those suffering from autoimmune conditions.

Germany

TolerogenixX vision is to innovate Immunosuppression with its newly developed MIC Cell Treatments. MIC Cell Treatment is a curative ATMP approach to achieve a sustained regulation of the immune system in Transplant - and Autoimmune Disease Patients. TolerogenixX has been able to generate strong pre-clinical as well as clinical data in the indications of Transplantation and Autoimmune Diseases e.g. SLE since its foundation in 2016. 

TolerogenixX

Company Details